Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps

NCT07616609 | Not Yet Recruiting

• 1 other identifier: TREC2026-KY074
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, randomized, double-blinded, placebo-controlled clinical trial in adults with moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have no previous nasal surgery. The purpose of this study is to evaluate the effectiveness and safety of using stapokibart for 4 weeks before endoscopic sinus surgery (ESS), compared with placebo before ESS. The main questions this study aims to answer are:

• Does preoperative stapokibart combined with endoscopic sinus surgery achieve better efficacy and comparable safety compared with surgery alone?
• What influences four-week preoperative stapokibart administration has on pharmacodynamic data and intraoperative surgical parameters？
• Is there a correlation between the efficacy of four-week stapokibart therapy and postoperative recurrence tendency after endoscopic sinus surgery? Researchers will randomly assign participants to receive either stapokibart or a placebo (an inactive substance that looks like the study drug) for 4 weeks before surgery. All participants will have the same standard endoscopic sinus surgery and will be followed for 48 weeks to check polyp status, symptoms, quality of life, and adverse events. This study will provide evidence about whether short-term preoperative stapokibart improves surgical and long-term outcomes for adults with CRSwNP undergoing ESS.

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Keywords

chronic rhinosinusitis with nasal polyps; nasal polyps; stapokibart; endoscopic sinus surgery; type 2 inflammation; randomized controlled trial; surgical outcome; preoperative biologic therapy; disease recurrence; double-blinded method; clinical safety; treatment efficacy

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Nasal Polyp Score (NPS) at Week 48 Postoperatively

  Nasal Polyp Score (NPS) is assessed bilaterally with 0-4 points per side (0 = no polyps, 4 = nearly complete nasal obstruction). Total score ranges 0-8; higher scores represent more severe polyposis. This outcome measures the change from baseline to 48 weeks after endoscopic sinus surgery.

  Baseline and Week 48 postoperatively

Secondary Outcomes (9)

• Change from Baseline in Total Nasal Symptom Score (TSS)

  Baseline, postoperative Week 2 , Week 4 , Week 12 , Week 24 , Week 36 , Week 48

• Change from Baseline in Nasal Symptom Visual Analog Scale (VAS) Score

  Baseline, postoperative Week 2 , Week 4 , Week 12 , Week 24 , Week 36 , Week 48

• Change from Baseline in 22-item Sino-Nasal Outcome Test (SNOT-22) Score

  Baseline, postoperative Week 2 , Week 4 , Week 12, Week 24 , Week 36 , Week 48

• Change from Baseline in Lund-Kennedy Endoscopic Score

  Baseline, postoperative Week 2 , Week 4 , Week 12 , Week 24 , Week 36, Week 48

• Change from Baseline in Lund-Mackay (LMK) Sinus CT Score at 48 Weeks Postoperatively

  Baseline and 48 weeks after endoscopic sinus surgery

Study Arms (2)

Stapokibart Treatment Group

EXPERIMENTAL

Eligible CRSwNP participants receive 300 mg stapokibart by subcutaneous injection every other week. Two weeks after the second injection, they undergo bilateral full-group sinus opening under general anesthesia via endoscopic sinus surgery. Postoperative follow-up lasted until 48 weeks. Throughout the entire study period, all participants receive routine maintenance treatment with nasal corticosteroid spray.

Biological: Stapokibart

Placebo Control Group

PLACEBO COMPARATOR

Eligible CRSwNP participants receive matched placebo by subcutaneous injection every other week. Two weeks after the second injection, they undergo bilateral full-group sinus opening under general anesthesia via endoscopic sinus surgery. Postoperative follow-up lasts until 48 weeks. Throughout the entire study period, all participants receive routine maintenance treatment with nasal corticosteroid spray.

Drug: Matched placebo

Interventions

Stapokibart BIOLOGICAL

Subcutaneous injection at a single dose of 300 mg, administered every other week for preoperative intervention. Bilateral endoscopic sinus surgery is performed after two injections. All participants receive standardized perioperative management and long-term follow-up up to 48 weeks.

Also known as: CM310, kangyueda

Stapokibart Treatment Group

Matched placebo DRUG

Matched inactive placebo for subcutaneous injection, with identical appearance, administration route and dosing interval. The preoperative intervention schedule, surgical procedure and 48-week follow-up arrangement are fully consistent with the stapokibart group.

Placebo Control Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Possess the ability to understand the nature of the study and voluntarily sign an informed consent form (ICF);
• Age between 18 and 75 years old, with no limitation on gender;
• Bilateral CRSwNP meeting the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2024);
• Persistent presence of the following symptoms for ≥12 weeks prior to the screening/introduction period:
• Nasal congestion;
• Any other symptom such as decreased/loss of smell or rhinorrhea;
• At the screening/introduction period and baseline, total NPS ≥ 4 points and NPS ≥ 2 points in each nasal cavity;
• At the screening/introduction period and baseline, the subject reports moderate to severe nasal congestion or decreased smell (NCS or LoS score of 2 or 3 points);
• During the screening/introduction period, the Lund-Mackay score on sinus CT is ≥12 points bilaterally and ≥6 points unilaterally;
• Must meet any of the following criteria for type 2 inflammation: Eosinophil count \>55/high-power field or eosinophil percentage \>27% in nasal polyp tissue during the induction period; eosinophil percentage ≥3.75% in peripheral blood in patients with asthma; eosinophil percentage ≥6.9% in patients without asthma;
• If the subject has asthma, the condition must be stable as assessed by the investigator or specialist. For subjects treated with a stable dose of inhaled corticosteroids for at least 4 weeks before screening, the treatment may be continued during the study period, and the daily dose of inhaled corticosteroids must be ≤1000 μg fluticasone propionate or an equivalent dose of other inhaled corticosteroids.

You may not qualify if:

• Previous ESS surgery including but not limited to septoplasty, turbinate reduction, nasal polyp removal, and sinus surgery;
• Contraindications to general anesthesia;
• Contraindications to stapokibart therapy;
• Previous use of any anti-IL-4Rα biologic;
• The patient has conditions or comorbidities that may prevent them from being evaluated for the primary efficacy endpoint, such as acute rhinitis, nasal infection or upper respiratory tract infection within 2 weeks prior to the screening period, acute asthma exacerbation within 4 weeks, current drug-induced rhinitis, allergic fungal sinusitis (AFRS), benign or malignant nasal tumors;
• Important clinical comorbidities that may interfere with clinical efficacy results, including but not limited to active upper or lower respiratory tract infection, cystic fibrosis, eosinophilic granuloma with polyangiitis (Churg-Strauss syndrome), granuloma with polyangiitis (Wegener's granulomatosis), Young's syndrome, etc.;
• Accompanied by other poorly controlled serious diseases or recurrent chronic diseases such as (but not limited to) active infection, cardiovascular disease, tuberculosis or other pathogen infection, diabetes, autoimmune diseases, HIV, hepatitis B, hepatitis C or parasitic diseases, malignant tumors, etc.;
• Subjects with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \> 2 times the upper limit of normal, and serum creatinine \> the upper limit of normal;
• Subjects with known or suspected immunosuppression, including those with a history of invasive opportunistic infections (such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cystitis, aspergillosis), even if the infection has subsided;
• Women who are pregnant or planning to become pregnant during the study period, or who are breastfeeding;
• Subjects of childbearing age who do not wish to use medically approved effective contraception;
• Subjects with a history of alcohol or drug abuse;
• Subjects deemed by the investigator to have other medical or non-medical conditions that make them unsuitable for participation in this study.

Sponsors & Collaborators

• Beijing Tongren Hospital: lead

Study Sites (1)

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China

Location

Related Publications (26)

• Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. [Guideline for diagnosis and treatment of chronic rhinosinusitis (2024)]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025 Mar 7;60(3):221-249. doi: 10.3760/cma.j.cn115330-20250116-00051. No abstract available. Chinese.

  PMID: 40147886 BACKGROUND

• Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, Lv W, Liu SX, Li PZ, Ou CQ, Xu G. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015 May;70(5):533-9. doi: 10.1111/all.12577. Epub 2015 Mar 4.

  PMID: 25631304 BACKGROUND

• Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021 Feb 11;14:127-134. doi: 10.2147/JAA.S290424. eCollection 2021.

  PMID: 33603409 BACKGROUND

• Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):565-72. doi: 10.1016/j.jaip.2016.04.012.

  PMID: 27393770 BACKGROUND

• Zhang L, Zhang Y, Gao Y, Wang K, Lou H, Meng Y, Wang C. Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma. Rhinology. 2020 Apr 1;58(2):126-135. doi: 10.4193/Rhin19.184.

  PMID: 31904028 BACKGROUND

• Pelletier A, Endam LM, Gonzalez E, Jannat S, Irani T, Desrosiers M. Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. Int Forum Allergy Rhinol. 2025 Mar;15(3):227-238. doi: 10.1002/alr.23471. Epub 2024 Oct 23.

  PMID: 39444257 BACKGROUND

• Homoe AS, Aanaes K, Tidemandsen JE, Holbaek HC, Niclas R, Badsberg SG, Holmegaard LBI, Backer V. Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6-Month Trial. Int Forum Allergy Rhinol. 2025 Jul;15(7):724-733. doi: 10.1002/alr.23562. Epub 2025 Mar 10.

  PMID: 40065601 BACKGROUND

• Garvey E, Naimi B, Duffy A, Hannikainen P, Kahn C, Farquhar D, Rosen M, Rabinowitz M, Toskala E, Nyquist G. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Int Forum Allergy Rhinol. 2024 Mar;14(3):651-659. doi: 10.1002/alr.23246. Epub 2023 Aug 10.

  PMID: 37506043 BACKGROUND

• Xian M, Yan B, Song X, Chen J, Tang J, Jiang Y, Wan L, Liu W, Xue J, Cao Z, Yu Y, Yang X, Shi L, Wang G, Xu Y, Yang Y, Ye J, Jiang L, Quan F, Tan G, Liu F, Xu Z, Zhang X, Li J, Su L, Yang Y, Fan J, He G, Zhu L, Wang X, Wang M, Shen S, Li J, Li H, Wei X, Yu H, Liu Z, Ma R, Liu H, Liu J, Lv W, Yang Q, Zhu D, Cheng L, Wang C, Zhang L. Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2025 May;80(5):1208-1225. doi: 10.1111/all.16519. Epub 2025 Mar 5.

  PMID: 40042059 BACKGROUND

• Xian M, Zhang L. Potential of biologics to alter the need for repeated surgery in patients with chronic rhinosinusitis with nasal polyps. Allergy. 2023 Mar;78(3):623-625. doi: 10.1111/all.15565. Epub 2022 Dec 5. No abstract available.

  PMID: 36301187 BACKGROUND

• Shen S, Yan B, Wang M, Wu D, Piao Y, Tang J, Yang X, Cao Z, Xue J, Liu W, Liu S, Shi L, Wang G, Song X, Lu Y, Chen J, Jiang L, Ye J, Yu S, Yang Y, Fang H, Li J, Shi H, Fan J, Yan H, Wang H, Chen B, Wang C, Zhang L; CROWNS-2 Study Investigators. Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial. JAMA. 2025 Aug 18;334(11):962-72. doi: 10.1001/jama.2025.12515. Online ahead of print.

  PMID: 40824573 BACKGROUND

• Zhang Y, Yan B, Shen S, Song X, Jiang Y, Shi L, Zhao C, Yang Y, Jiang L, Li J, Ye J, Liu J, Wan L, Yang Y, Chen J, Liu F, Su L, Xu Y, Tan G, Yu S, Zhang Y, Wang L, Liu S, Yan H, Liu W, Chen B, Wang C, Zhang L. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5;61:102076. doi: 10.1016/j.eclinm.2023.102076. eCollection 2023 Jul.

  PMID: 37483544 BACKGROUND

• Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015 Sep-Oct;29(5):350-6. doi: 10.2500/ajra.2015.29.4231. Epub 2015 Jul 27.

  PMID: 26219765 BACKGROUND

• Shah SA, Ishinaga H, Takeuchi K. Pathogenesis of eosinophilic chronic rhinosinusitis. J Inflamm (Lond). 2016 Apr 6;13:11. doi: 10.1186/s12950-016-0121-8. eCollection 2016.

  PMID: 27053925 BACKGROUND

• Toppila-Salmi S, Reitsma S, Hox V, Gane S, Eguiluz-Gracia I, Shamji M, Maza-Solano J, Jaaskelainen B, Vaara R, Escribese MM, Chaker A, Karavelia A, Rudenko M, Gevaert P, Klimek L. Endotyping in Chronic Rhinosinusitis-An EAACI Task Force Report. Allergy. 2025 Jan;80(1):132-147. doi: 10.1111/all.16418. Epub 2024 Dec 6.

  PMID: 39641584 BACKGROUND

• Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S, Horowitz JE, Sacks H, Jacob-Nara JA. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol. 2024 Apr 16;15:1356298. doi: 10.3389/fimmu.2024.1356298. eCollection 2024.

  PMID: 38690264 BACKGROUND

• Yu J, Xian M, Piao Y, Zhang L, Wang C. Changes in Clinical and Histological Characteristics of Nasal Polyps in Northern China over the Past 2-3 Decades. Int Arch Allergy Immunol. 2021;182(7):615-624. doi: 10.1159/000513312. Epub 2021 Feb 17.

  PMID: 33596581 BACKGROUND

• Tsuda T, Suzuki M, Kato Y, Kidoguchi M, Kumai T, Fujieda S, Sakashita M. The current findings in eosinophilic chronic rhinosinusitis. Auris Nasus Larynx. 2024 Feb;51(1):51-60. doi: 10.1016/j.anl.2023.08.002. Epub 2023 Aug 11.

  PMID: 37574421 BACKGROUND

• Wang M, Wang C, Zhang L. Inflammatory endotypes of CRSwNP and responses to COVID-19. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):8-15. doi: 10.1097/ACI.0000000000000700.

  PMID: 33164997 BACKGROUND

• Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N, Rowe P, Maroni J, Eckert L, Yang T, Khan A. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019 Sep;129(9):1969-1975. doi: 10.1002/lary.27852. Epub 2019 Feb 5.

  PMID: 30720213 BACKGROUND

• De Corso E, Bilo MB, Matucci A, Seccia V, Braido F, Gelardi M, Heffler E, Latorre M, Malvezzi L, Pelaia G, Senna G, Castelnuovo P, Canonica GW. Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement. J Pers Med. 2022 May 23;12(5):846. doi: 10.3390/jpm12050846.

  PMID: 35629268 BACKGROUND

• Tamene S, Dalhoff K, Schwarz P, Backer V, Aanaes K. Systemic corticosteroids in treatment of chronic rhinosinusitis-A systematic review. Eur Clin Respir J. 2023 Aug 4;10(1):2240511. doi: 10.1080/20018525.2023.2240511. eCollection 2023.

  PMID: 37554567 BACKGROUND

• Milara J, Morell A, Ballester B, Armengot M, Morcillo E, Cortijo J. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017 Mar;139(3):855-862.e13. doi: 10.1016/j.jaci.2016.06.064. Epub 2016 Sep 14.

  PMID: 27639937 BACKGROUND

• Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, Broker BM, Laidlaw T, Song WJ. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 Oct 29;6(1):86. doi: 10.1038/s41572-020-00218-1.

  PMID: 33122665 BACKGROUND

• Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.

  PMID: 32077450 BACKGROUND

• Wang W, Kang T, Zhu Z, Wu M, Lv W. Optimal Timing of Dupilumab Application in CRSwNP: Impact of "Neoadjuvant Therapy" on Surgical Outcomes at 1 Year. Int Forum Allergy Rhinol. 2025 Oct;15(10):1175-1177. doi: 10.1002/alr.70014. Epub 2025 Aug 18.

  PMID: 40825084 RESULT

MeSH Terms

Conditions

Nasal Polyps

Condition Hierarchy (Ancestors)

Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Polyps; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Mu Xian, MD

  Beijing Tongren Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mu Xian, MD

CONTACT

+86 13671138761; mu_xian@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician, Professor

Model Details: This is a single-center, randomized, double-blind, placebo-controlled parallel-group trial. Eligible patients are randomly divided into two independent groups. The experimental group receives preoperative stapokibart injection, while the control group receives matched placebo. All subjects undergo standardized endoscopic sinus surgery and identical postoperative management with long-term follow-up.

Study Record Dates

• First Submitted: May 20, 2026
• First Posted: June 1, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: June 1, 2026

Record last verified: 2026-05

Locations

CN (1)